Abstract
We read the two articles published in a recent issue of Diabetes Care by Lewis et al. (1) and Ferrara et al. (2) with interest. The first study tested a time-dependent use of pioglitazone for the risk of bladder cancer among 193,099 diabetic patients in the Kaiser Permanente Northern California Diabetes Registry and concluded that use of the drug over 24 months was associated with an increased risk of bladder cancer (hazard ratio 1.4, 95% CI 1.03–2.0). The second study tested a time-dependent use of pioglitazone for the risk of cancer among 252,467 diabetic patients aged ≥40 years from the Kaiser Permanente Northern California Diabetes Registry and found that ever use of pioglitazone was not …
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call